Exchange: NASDAQ·Updated 04:49 AM EDT

BRVE Braveheart Bio Inc.

$21.19
$1.40
(7.07%)
Pre-Market
Prev Close $19.79
Reported EarningsSep 8
Mkt Cap$1.78B
Vol7.00

About BRVE

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
31

Bearish Sentiment

How do you feel about BRVE?

Advertisement|Remove ads.